13 completed, 2 terminated, 2 unknown, 2 withdrawn. 21 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Completed 13, Terminated 2, Unknown 2, Withdrawn 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Major Depression: new trials by email Literature Review of Major Depression trials Research Report on Major Depression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression Psilocybin - Major Depression | Phase 3 | Recruiting | VA Office of Research and Development | 240 | 2026-08-03 | 2026-10-23 |
| Transcranial Magnetic Stimulation in Patients with Dual Disorders Repetitive Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham - Major Depression, Tobacco Addiction | Phase 3 | Not yet recruiting | Cardenal Herrera University | 36 | 2025-02-01 | 2025-01-09 |
| Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI) Vortioxetine, Placebo - TBI, Major Depression | Phase 3 | Withdrawn | Johns Hopkins University | 2016-10-01 | 2016-09-02 | |
| Omega 3 FA Supplements as Augmentation in the Treatment of Depression Desvenlafaxine, Omega 3 Fatty acids, Placebo (for Omega 3 fatty acid supplement) - Major Depression, Cancer | Phase 2 / Phase 3 | Terminated | UConn Health | 6 | 2013-02-01 | 2017-12-27 |
| CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care Cognitive behavior therapy, Return to work - Anxiety Disorders, Major Depression | Phase 3 | Completed | Karolinska Institutet | 211 | 2012-09-01 | 2016-03-03 |
| Cognitive Behavioral Therapy, Guided Self Help Versus Individual Therapy Continued self help CBT, Individual CBT - Anxiety Disorders, Major Depression | Phase 3 | Completed | Karolinska Institutet | 396 | 2012-08-01 | 2016-10-18 |
| CBT vs RTW Intervention for Patients With Common Subclinical Mental Illness in Primary Care Cognitive behavior therapy, Return to work - Anxiety Disorders, Major Depression | Phase 3 | Completed | Karolinska Institutet | 5 | 2012-08-01 | 2016-03-03 |
| Efficacy and Safety of Homeopathy for Moderate Depression (Acute Phase) homeopathic q-potencies, Placebo, homeopathic case history taking type I - Major Depression | Phase 3 | Terminated | Charite University, Berlin, Germany | 44 | 2010-08-01 | 2012-07-10 |
| Long-term Bilateral Theta Burst Stimulation for the Treatment of Major Depression Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS) - Major Depression | Phase 2 / Phase 3 | Completed | University Hospital Tuebingen | 32 | 2010-04-01 | 2013-07-16 |
| Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients quetiapine, escitalopram - Major Depression | Phase 3 | Completed | Ludwig-Maximilians - University of Munich | 60 | 2009-09-01 | 2013-02-12 |
| Escitalopram (Lexapro) for Depression MS or ALS escitalopram - Major Depression, Multiple Sclerosis | Phase 3 | Completed | University of South Carolina | 13 | 2009-07-01 | 2019-05-01 |
| A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder SR58611A - Depressive Disorder, Major Depression | Phase 3 | Completed | Sanofi | 704 | 2006-05-01 | 2009-03-12 |
| Magnetic Seizure Therapy (MST) for Treatment Resistant Major Depression Thymatron, Tonica MagPro MST - Major Depression | Phase 3 | Completed | University Hospital, Bonn | 30 | 2005-02-01 | 2018-08-06 |
| Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression antidepressant medications, flexible drug choice, CBT, Psychodynamic or Supportive Psychotherapy - Major Depression | Phase 3 | Unknown | Sir Mortimer B. Davis - Jewish General Hospital | 30 | 2004-08-01 | 2005-09-22 |
| The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning Razadyne, Placebo - Major Depression, Bipolar Depression | Phase 3 | Completed | Massachusetts General Hospital | 39 | 2004-07-01 | 2012-12-03 |
| PUFA Augmentation in Treatment of Major Depression Polyunsaturated Fatty Acids (PUFA), Citalopram - Major Depression | Phase 3 | Completed | National Center for Complementary and Integrative Health (NCCIH) | 60 | 2003-09-01 | 2008-01-25 |
| Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to a Trial of Antidepressant Risperidone - Major Depression | Phase 3 | Unknown | Rhode Island Hospital | 84 | 2003-02-01 | 2005-09-15 |
| Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression. triiodothyronine, sertraline - Major Depression, Bipolar Disorder | Phase 3 | Completed | Hadassah Medical Organization | 220 | 2002-10-01 | 2007-01-04 |
| Discontinuation Study Of Citalopram (Antidepressant) in Depressed Adolescents Citalopram - Major Depression | Phase 3 | Withdrawn | Sunnybrook Health Sciences Centre | 60 | 2002-09-01 | 2006-09-19 |
| Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression Selegiline Transdermal System - Major Depression | Phase 3 | Completed | Somerset Pharmaceuticals | 300 | 2002-08-01 | 2008-04-22 |
Showing 20 of 21. Sign in to see all of them.
Depressive Disorder, Major (21) · Depression (9) · Anxiety Disorders (3) · Sleep Initiation and Maintenance Disorders (3) · Stress Disorders, Traumatic (3) · Bipolar Disorder (2) · Depressive Disorder (2) · Psychotic Disorders (2) · Amyotrophic Lateral Sclerosis (1) · Cardiovascular Diseases (1) · Diabetes Mellitus (1) · Hypertension (1) · Mood Disorders (1) · Multiple Sclerosis (1) · Neoplasms (1)
Mental Disorders (21) · Mood Disorders (20) · Depressive Disorder (19) · Behavior (9) · Behavioral Symptoms (9) · Nervous System Diseases (4) · Trauma and Stressor Related Disorders (4) · Dyssomnias (3) · Sleep Disorders, Intrinsic (3) · Sleep Wake Disorders (3) · Bipolar and Related Disorders (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Schizophrenia Spectrum and Other Psychotic Disorders (2) · Autoimmune Diseases (1)
Citalopram (2) · Cognitive Behavioral Therapy (2) · Escitalopram (2) · Return to Work (2) · Transcranial Magnetic Stimulation (2) · Amibegron hydrochloride (1) · Desvenlafaxine Succinate (1) · Fatty Acids, Omega-3 (1) · Fatty Acids, Unsaturated (1) · Galantamine (1) · Leucovorin (1) · Psilocybin (1) · Pyrimethamine (1) · Quetiapine Fumarate (1) · Risperidone (1)
Karolinska Institutet (3) · Cardenal Herrera University (1) · Charite University, Berlin, Germany (1) · Hadassah Medical Organization (1) · Johns Hopkins University (1) · Ludwig-Maximilians - University of Munich (1) · Massachusetts General Hospital (1) · National Center for Complementary and Integrative Health (NCCIH) (1) · Rhode Island Hospital (1) · Sanofi (1) · Sir Mortimer B. Davis - Jewish General Hospital (1) · Somerset Pharmaceuticals (1) · Sunnybrook Health Sciences Centre (1) · UConn Health (1) · University Hospital Tuebingen (1)
United States (8) · Germany (4) · Sweden (3) · Canada (2) · Argentina (1) · Bulgaria (1) · Croatia (1) · Czechia (1) · Finland (1) · France (1) · Israel (1) · Mexico (1) · Poland (1) · Romania (1) · Russia (1)
Alejandro Fuertes, Associate Professor (1) · Anthony J Levitt, MD (1) · Bernard Lerer, MD (1) · Claudia M. Witt, MD (1) · Dunja Hinze-Selch, MD (1) · Gabor I Keitner, M.D. (1) · Jayesh Kamath, MD PhD (1) · John C Perry, M.P.H., M.D. (1) · John D Matthews, MD (1) · Lev Gertsik, MD (1) · Lori Lynne Davis, MD AB (1) · Meera Narasimhan, MD (1) · Thomas E. Schlaepfer, MD (1) · Vani Rao, MD (1)
PMID 17548749, PMID 24086352, PMID 24275013, PMID 34131914, PMID 34817851
2009 (1), I01RD001520 (1)